Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Live vaccines against fowlpox virus, which causes moderate pathology in poultry and is the type species of the Avipoxvirus genus, were developed in the 1920s. Development of recombinant fowlpox virus vector vaccines began in the 1980s, for use not only in poultry, but also in mammals including humans. In common with other avipoxviruses, such as canarypox virus, fowlpox virus enters mammalian cells and expresses proteins, but replicates abortively. The use of fowlpox virus as a safe vehicle for expression of foreign antigens and host immunomodulators, is being evaluated in numerous clinical trials of vaccines against cancer, malaria, tuberculosis and AIDS, notably in heterologous prime-boost regimens. In this article, technical approaches to, and issues surrounding, the use of fowlpox virus as a recombinant vaccine vector in poultry and mammals are reviewed.

Original publication

DOI

10.1586/14760584.4.1.63

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

02/2005

Volume

4

Pages

63 - 76

Keywords

Animals, Antigens, Neoplasm, Cancer Vaccines, Clinical Trials as Topic, Drug Delivery Systems, Drug Evaluation, Preclinical, Fowlpox virus, Genetic Vectors, History, 20th Century, Humans, Mardivirus, Marek Disease, Marek Disease Vaccines, Melanoma, Poultry, Vaccination, Vaccines, Synthetic, Viral Vaccines